UBS: Maintains "Buy" rating on HUTCHMED (00013), target price HK$29.5

date
15:45 20/11/2026
avatar
GMT Eight
Sovleplenib (a Syk inhibitor) has been approved in China via priority review for the treatment of ITP and wAIHA, which the bank views as positive and better than expected.
UBS released a research report stating that Sovleplenib (a Syk inhibitor) has been approved in China via priority review for the treatment of ITP and wAIHA, which the bank views as positive and better than expected. The bank maintains its "Buy" rating on HUTCHMED (00013) with a target price of HK$29.5. The bank noted that Sovleplenib is China's first and only approved Syk inhibitor, with the approval supported by the ESLIM-01/02 studies. The bank estimates peak sales of US$327 million by 2035, versus market expectations of US$241 million. The next key focus will be updates on the overseas development strategy.